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Fructose 2,6-bisphosphate has been claimed to be both a substrate analogue and an allosteric inhibitor of 
fructose-1,dbisphosphatase. Th  results reported here show that fructose 2,6-bisphosphate can be both 
an inhibitor and an activator of the enzyme, depending on the substrate concentration. This biphasic 
behaviour at saturating concentrations of substrate can only be due to an allosteric effect. In addition to 
the mechanistic implication it is possible that this finding may have physiological meaning. 
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1. INTRODUCTION 
The interconversion of fructose 6-phosphate 
(F6P) and fructose 1,6-bisphosphate (F-1,6-Pz) is 
catalyzed by two antagonistic enzymes, 
6-phosphofructokinase and fructose-l ,6-bisphos- 
phatase (FBPase) that are both subject to 
multimodulation by a variety of effecters whose 
action on one enzyme is usually opposite to that on 
the other [l]. Fructose-2,6-Pz (F-2,6-Pz) has been 
shown to be the most potent of such effecters as 
regards activation of the phosphofructokinase and 
to have an inhibitory effect on FBPase [2-81. The 
mechanism of the inhibitory action has been the 
subject of controversy, with one group of in- 
vestigators providing evidence for an allosteric 
type of interaction [3,5,6] while others claimed it 
to be competitive inhibition [7-131. In the course 
of our studies on the action of hexose 
bisphosphates on key glycolytic enzymes we were 
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Hepes (N-2-hydroxethylpiperazine-N’-Zethane- 
sulphonic acid), Pipes (piperazine-N,N’ -bis- 
(Zethanesulphonic acid)), EGTA, F-l ,6-Pz, 
F-2,6-Pz, NADP, AMP and the auxiliary enzymes 
were purchased from Sigma (St. Louis, MO); im- 
idazole was from Scharlau (Barcelona); Sephadex 
G-25 was from Pharmacia (Uppsala). Other 
chemicals were purchased 
(Milano). 
* To whom correspondence should be addressed F-1,6-Pz was treated at pH 
Aliosteric modulation 
surprised to find that F-2,6-Pz is an inhibitor of 
FBPase only at low concentrations of the 
substrate, while becoming an activator at higher 
concentrations. Furthermore, at fixed substrate 
concentrations, the effector may be either positive 
or negative, depending on its own concentration. 
These effects are enhanced by certain commonly 
used buffers. Here we report our observations in 
this regard, and discuss the possible physiological 
role of this phenomenon. 
2. MATERIALS AND METHODS 
2.1. Chemicals and enzymes 
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for 10 min at room temperature and then adjusted 
to pH 7 (with 0.5 N KOH) to prevent a possible 
contamination of F-2,6-P2. 
2.2. Partial purification of fructose-l,Gbisphos- 
phatase 
The enzyme was partially purified from rat liver 
as in [14], but instead of the gel fractionation 
steps, the enzyme was precipitated with am- 
monium sulphate, and the 35 to 60% fractions 
were collected. The enzyme was desalted through 
Sephadex G-25 prior to use. The specific activity of 
this preparation was 30 pmol F-l,6-P2 hydro- 
lyzed . min- ’ . mg protein-‘. The protein was 
measured as in [15]. Aldolase content was lower 
than 0.4%. 
2.3. Assay of fructose-l,&bisphosphatase 
The enzymatic activity was measured spectro- 
photometrically. The standard assay contained, in 
final concentrations: 50 mM buffer at pH 7.2 
(Pipes, Hepes or imidazole), 100 mM KCl, 1 mM 
MgS04, 1 mM NH&l, 5 mM EGTA, 0.5 mM 
NADP, 5 pg glucosed-phosphate dehydrogenase 
and 20 pg glucose-phosphate isomerase, both 
desalted through Sephadex G-25, in a final volume 
of 1 ml. F- 1,6-P2 and AMP were added at the con- 
centrations indicated on the bottom of the figures; 
when the assay was performed without buffer, the 
reaction mixture was brought to pH 7.2 (with 0.5 
N KOH) and the p&I was maintained mainly by the 
low buffer capacity of EGTA. FBPase was in- 
cubated with this assay mixture for 5 min at 37°C 
and the reaction was initiated by the addition of 
10-40~1 F-l,6-P2 to obtain the concentration as in- 
dicated in each figure legend. 
3. RESULTS 
3.1. Effect of F-2,6-PZ at different substrate 
concentrations 
The effect of 1 gM F-2,6-P2 on the activity of 
FBPase was measured at different concentrations 
of F-l ,6-P2. As can be seen in fig. 1, 1 PM F-2,6-P2 
inhibits the enzyme activity within the range 5-20 
/cM F-l,6-P2. As the concentration of F-l,6-P2 in- 
creases, F-2,6-P2 becomes an activator, and the 
positive effect is observed at all higher concen- 
trations tested. This activatory behaviour of 
200 
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Fig. 1. Effect of 1 ,uM F-2,6-P2 on FBPase activity at 
different concentrations of substrate. (0,O) control; 
(0, l ) with F-2,6-P2; (0,o) Hepes; (0 ,m) Pipes; for 
more details ee section 2. 
F-2,6-P2 is relatively greater when Pipes, rather 
than Hepes, buffer is used. 
3.2. The effect of varying F-2,6-P2 concentration 
To determine whether or not the biphasic effect 
of F-2,6-P2 was dependent on the effector concen- 
tration at a fixed F-l,6-P2 concentration, the ac- 
tivity of the enzyme was measured at 20 and 200 
PM substrate. As can be seen in fig.2A a clear ac- 
tivation effect is seen at low F-2,6-P2 that falls off 
rapidly as the concentration of the effector reaches 
5 PM and above. Note that the extent, but not the 
quality, of the effect depends on the buffer used. 
Thus, maximal activations were obtained with 1 
pM F-2,6-P2. However, while in Pipes the activa- 
tion was almost 2-fold, in Hepes and in imidazole 
only a 50% increase in activity was observed. Fur- 
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Fig. 2. Effect of F-2,6-P2 and AMP on rat liver FBPase 
at 20 PM F-l ,6-P2. (A) Without AMP, (B) with 10 pM 
AMP. Buffers: (m) Pipes; (0) Hepes; (A) imidazole. 
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thermore, at 5 PM F-2,6-Pz a moderate activation 
could be seen in Pipes, while 50% inhibition was 
apparent in both Hepes and imidazole. The inhibi- 
tion becomes more pronounced reaching about 
90%, when F-2,6-P2 concentration approaches 
that of F-1,6-Pz. In fig.2B it can be seen that 10pM 
AMP displaces all curves downwards and to the 
left without changing their slope. It is thus ob- 
served that the activatory effect at low F-2,6-Pz 
concentrations is smaller and that the inhibitory 
effect of the metabolite is quite pronounced at 
lower concentrations of F-2,6-P2. Qualitatively 
similar results were obtained at 200 pM F-l,6-Pz, 
although the inhibition by F-2,6-Pz was smaller 
than at 20 PM and AMP enhanced the effect of 
F-2,6-P2 in all buffers used (not shown). 
4. DISCUSSION 
Authors in [5] and in [7] independently reported 
in 1981 that F-2,6-P2 is an inhibitor of FBPase. 
Following these initial reports the first group has 
obtained evidence suggesting that the effect is 
allosteric [5,6], while the second group has 
published results concluding that F-2,6-Pz behaves 
as a competitive inhibitor substrate analogue 
[7-131. That the effect is allosteric is suggested by 
the fact that F-2,6-Pz seems to change the kinetics 
of the enzyme toward its substrate from hyperbolic 
to sigmoid [5-121, that its effect is synergistic with 
the allosteric inhibitor AMP [5,8], and that dif- 
ferent physical conditions and chemical reagents 
affect F-2,6-Pz and AMP actions in parallel. In ap- 
parent contraposition to these observations it has 
been shown that the inhibitory effect is larger at 
low than at high concentrations of substrate 
[3,5,6,12], that treatments that affect AMP bind- 
ing do not necessarily affect F-2,6-Pz action [12], 
and that product analogues thought to act at the 
active site give kinetic plots similar to those ob- 
tained with F-2,6-Pt [lo]; these results have been 
interpreted to mean that F-2,6-Pz acts as a sub- 
strate analogue. However, as pointed out in [8] the 
available data could also be interpreted to mean 
that F-2,6-Pz acts both at the active and at an 
allosteric site. Binding studies seem to confirm that 
F-2,6-P2 binds at a site which is the same or close 
to the active site, as shown by the fact that F-2,6-Pz 
binding is competitively inhibited by F-l ,6-Pz, 
F-6-P and Pi, while AMP does not affect F-2,6-P2 
binding [13]. Nevertheless, more recently it has 
been reported that rat liver FBPase has two bind- 
ing sites for F-2,6-Pz, the catalytic site and an 
allosteric site [ 161. 
Our finding that F-2,6-Pz can activate FBPase at 
high concentrations of substrate authenticates the 
allosteric nature of the stronger inhibition ob- 
served at more physiological concentrations of 
substrate. An isosteric analogue could not exhibit 
the biphasic behaviour reported here. 
Although our results indicate that the main ef- 
fect of F-2,6-Pz is allosteric, they do not preclude 
that when the concentration of the effector ap- 
proaches or surpasses that of the substrate, com- 
petition for the active site might contribute to the 
overall effect. The fact that the activation at 
relatively low F-1,6-Pz concentrations had not 
been previously observed might be due to the 
relative concentrations of F-l ,6-Pz and F-2,6-Pz 
and by the buffers used by other authors. 
While the activation of F-2,6-P2 might not have 
physiological significance under most cir- 
cumstances, it should be pointed out that at 20pM 
F-l,6-P2, l-3 PM F-2,6-Pz causes an activation 
rather than inhibition of FBPase in all buffers 
tested. The levels of F-1,6-P2 in rat liver are in the 
range 5-32 nmol/g [17], the lowest value cor- 
responding to starved animals. On the other hand, 
the levels of F-2,6-Pz also change with the nutri- 
tional state from about 1 to 9 nmol/g cells [18]. 
Our findings and the physiological concentration 
of the bisphosphates may correlate in the sense 
that under gluconeogenic onditions, F-2,6-P2 will 
either not inhibit or may actually cause a slight ac- 
tivation of the FBPase. 
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